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Antibody-mediated osseous regeneration (AMOR) has been introduced by our research group as a tissue engineering approach
to capture of endogenous growth factors through the application of specific monoclonal antibodies (mAbs) immobilized on a
scaffold. Specifically, anti-Bone Morphogenetic Protein- (BMP-) 2 mAbs have been demonstrated to be efficacious in mediating
bone repair in a number of bone defects.The present study sought to investigate the application of AMOR for repair of mandibular
continuity defect in nonhuman primates. Critical-sized mandibular continuity defects were created inMacaca fascicularis locally
implanted with absorbable collagen sponges (ACS) functionalized with chimeric anti-BMP-2 mAb or isotype control mAb. 2D and
3D analysis of cone beam computed tomography (CBCT) imaging demonstrated increased bone density and volume observed
within mandibular continuity defects implanted with collagen scaffolds functionalized with anti-BMP-2 mAb, compared with
isotype-matched control mAb. Both CBCT imaging and histologic examination demonstrated de novo bone formation that was
in direct apposition to the margins of the resected bone. It is hypothesized that bone injury may be necessary for AMOR. This is
evidenced by de novo bone formation adjacent to resected bone margins, which may be the source of endogenous BMPs captured
by anti-BMP-2 mAb, in turn mediating bone repair.
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1. Introduction
Loss of mandibular bone due to congenital anomalies,
trauma, infection, or tumor resection surgeries is a chal-
lenging clinical problem for reconstruction. Currentmethods
for repair or regeneration include autologous bone grafting,
allogenic bone grafting, and tissue engineering [1–3]. For
several decades, the most widely used procedures to promote
healing of bone fractures and large defects utilized autologous
or allogenic bone grafts [1]. However, the use of these
materials has a number of drawbacks including potential
host reaction, limited donor tissue availability, donor-site
morbidity, and potential disease transmission from allografts
[4]. An alternative to bone grafts is bone tissue engineering.
Tissue engineering entails the application of progenitor cells
and/or growth factors delivered to the treatment site on an
acellular scaffold. It is well known that bone tissue engineer-
ing is partially regulated by the host local microenvironment,
including the presence of signaling molecules and host
immune cells [5–7]. Bone Morphogenetic Proteins (BMPs)
are potential osteoinductive growth factors that play a critical
role in bone regeneration and repair [8]. It is well known
that exogenous administration of recombinant human (rh)
BMP-2 can initiate a healing cascade that mediates bone
regeneration through the TGF-𝛽/BMP signaling pathway
[8]. Owing to their substantial osteogenic properties, the
US Food and Drug Administration (FDA) had approved
rhBMP-2 and rhBMP-7 for clinical use [9, 10]. However,
application of exogenous growth factors also has a number of
drawbacks, including serious adverse effects which are occa-
sionally fatal; moreover, recombinant growth factors have
reduced biological activity, requiring high concentrations
to be used in vivo and therefore are associated with high
costs [5, 11–13]. These shortcomings have driven the quest
for the development of alternative strategies. Our research
group has introduced an alternative bone tissue engineering
approach termed antibody-mediated osseous regeneration
(AMOR). We have identified specific monoclonal antibody
(mAb) clones directed against BMP-2 that have the ability
to capture endogenous BMP-2 ligands and present them to
progenitor cells, mediating in vivo tissue repair [14]. Ansari
et al. reported that AMOR can be regulated through BMP
signaling pathway [15]. In addition, it was confirmed that
anti-BMP-2 mAb can trap and tether endogenous BMP-2
ligands for the directed osteodifferentiation of mesenchymal
stem cells through in vitro and in vivo studies [16]. In
previous studies, murine and chimeric anti-BMP-2 mAb has
been used in mice, rat, and rabbit models and confirmed
to be effective in promoting bone repair and regeneration
through calvaria defect models [17–20]. However, there has
been a need for more clinically relevant animal models.
Specifically, more relevant animal models for craniofacial
reconstructive surgeries are desired. Before a novel approach
like this one can be introduced into a clinical trial, preclinical
studies should be available in larger animal models that more
closely mimic challenging human clinical skeletal defects.
Therefore, in the present study, we investigated the ability of
chimeric anti-BMP-2 mAb to mediate repair of a critical-size
mandibular continuity defect in a nonhuman primate model.
2. Materials and Methods
2.1. Animals. All animal experiments were performed in
accordance with a protocol approved by the Institutional
Animal Care and Use Committee (IACUC) of the Capital
MedicalUniversity, Beijing, China. Six adultmale crab-eating
macaques (Macaca fascicularis) aged 8–12 and weighing
between 4.0 and 5.0 kg were included in this study. Three
animals were assigned to experimental (AMOR) and 3 to
control (isotype-matched mAb) groups. Before surgery, the
animals were housed in individual cages with water and fed
ad libitum.
2.2. Antibody. The hybridoma clone of a murine anti-BMP-2
mAb was expanded and used in order to generate chimeric
anti-BMP-2 mAb according to procedures described by
Ansari et al. [15]. Based on previous dose-response data,
25 𝜇g/mL was selected as the optimal dose of chimeric anti-
BMP-2 mAb for all experiments [15, 18].
2.3. Scaffold Biomaterials. Chimeric anti-BMP-2 mAb
(25 𝜇g/mL) and isotype control mAb (25𝜇g/mL) were
adsorbed on type 1 absorbable collagen sponge (ACS;
CollaCote: Integra, Plainsboro, NJ, USA) as previously
described [17]. Briefly, ACS was saturated in diluted mAb for
one hour at room temperature prior to in vivo implantation.
2.4. Mandibular Defect Model. Six animals were randomly
assigned into experimental or control groups. The three
animals in the control group received ACS immobilized
with isotype-matched control mAb and the three experi-
mental animals received ACS immobilized with chimeric
anti-BMP-2 mAb in their defects. Animals were sedated
with subcutaneous injection of 5mg/kg of ketamine (Jiangsu
Hengrui Medicine Co., Ltd, Lianyungang, China). Anes-
thesia was achieved by veterinarian staff with IV Propo-
fol (8mg/kg; Diprivan, Astra Zeneca, London, England).
Endotracheal intubation was performed using an oral-
tracheal tube with a diameter of 3.5mm (Sheridan, Tele-
flex Medical, NC, USA). The anesthesia was maintained
by IV Propofol (2.5mg/kg) per 30∼45min. Local anesthesia
was achieved by intramucosal injection of lidocaine with
1 : 100,000 epinephrine (Astra Zeneca, London, England) [21,
22]. Hair over the right mandibular region was shaved. The
animals were swabbed periorally with 1% Cetrimide followed
by 0.05% chlorhexidine gluconate solution. All surgical sites
were washed with 0.12% chlorhexidine gluconate solution. In
each animal, a 4 cm submandibular incisionwasmade at 1 cm
below the inferior border of the mandible, after which the
platysma was identified and cut, taking care not to damage
the mandibular branch of the facial nerve. The facial artery
and vein were then identified, tied off, and ligated. The mas-
seter muscle was then identified and dissected to reach the
periosteal layer. The periosteum was incised and elevated to
expose themandible to the region of the first molar anteriorly
and halfway up the ascending ramus posteriorly. Preoperative
CBCT images were taken in order to aid with planning the
segmental osteotomies (Figure 1(a)). Reconstruction plates
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Figure 1: Representative clinical and 3D-rendered imaging volume of mandibular continuity defects. Preoperative CBCT images (a) were
used to aid in planning of the segmental osteotomy, as well as in comparison with postsurgical images. Clinical view, showing the surgically
exposed posterior mandible, where the reconstruction plates were provisionally attached to the mandible (b). This step defined the position
of the titanium screws and reconstruction plates relative to the planned osteotomy to aid in orienting the segmented ends following resection
back in correct position. Resected segmental osteotomy, creating a 1.5 cm continuity defect (c). Repositioned mandibular segments fixated
with titanium reconstruction plates (d).
were provisionally attached to the mandible over the region
planned for resection, prior to osteotomy (Figure 1(b)).
This step defined the position of the titanium screws and
reconstruction plates relative to the planned osteotomy to
help with orienting the segmented ends, following resection
back in correct position. A 1.5 cm wide segmental osteotomy
of the mandible was performed on the right angle of
mandible, using a rotary fissure bur under copious irrigation
(Figure 1(c)).Themandibular segmentswere reoriented using
the positions of the predrilled titanium screws as a guide.
The segments were fixated with 2 titanium reconstruction
plates using two titanium screws per plate (Figure 1(d)).
ACS scaffold (4.0 cm × 2.0 cm × 3.0mm), which was
preincubated with anti-BMP-2 or isotype-matched control
mAb, was placed within experimental or control transected
defect sites, respectively. Since the scaffolds were spongy in
consistency, once incubated with 100 𝜇L of anti-BMP-2 or
isotype control mAb, they easily adapted to the confines
of the defects. The incision was approximated primarily
in layers using polyglactin sutures (Vicryl, Ethicon Inc,
Somerville, NJ, USA). The skin was covered with 3% tetra-
cycline hydrochloride antibiotic ointment. Postoperative care
included analgesia by IM injection of Carprofen (2mg/kg;
Harbin Pharmaceutical Group, Co., Ltd, Harbin, China) for 3
days postoperatively. Animals were maintained on a soft diet
for 2 weeks postoperatively. Oral hygiene measure consisted
of spraying the teeth of animals with 0.2% chlorhexidine
gluconatemouthwash (Etouch, Shandong, China) once a day.
2.5. Cone Beam Computed Tomography (CBCT) Image Anal-
ysis. Live animals were imaged with CBCT scanner (Kodak
Medical Solutions Molecular Imaging, Knoxville, TN) with
60 𝜇m voxel size at 60 kV and 110mA at three time points
(preoperatively, as well as at 6 and 12 weeks postoperatively).
The data were acquired in Digital Imaging and Communi-
cations in Medicine (DICOM) format. For two-dimensional
analysis, DICOM files were imported into Simplant Pro
16.0 Software (Dentsply Implants, Waltham, MA, USA) for
2D and 3D image reconstruction and density analysis. The
minimum threshold used for reconstruction of 3D volumes
was set at 400 Hounsfield units (HU), based on the lowest
density observedwithin control and experimental specimens.
This threshold was used for all pre- and postoperative images
at all time points. Pre- and postoperative (6 and 12 weeks after
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surgery) CBCT images were examined for 2D quantitative
analysis of de novo bone formation by density measure-
ments within sections taken in axial planes. For analysis of
axial images, 3 sections were taken at equal distances from
the superior-most through inferior-most boundaries of the
defects. The density measurements were performed, using
rectangle density measurement tool in Simplant software in
each of the sections, and the density was recorded in HU.
Titanium plates were excluded from analysis of density.
3D image analysis was performed as previously described
[22]. Briefly, DICOM files were imported into Mimics
software (Materialise, Leuven, Belgium) to construct 3D
volumes.The reconstructions of scanned images were thresh-
olded to remove any soft tissue and cartilage, leaving only
mineralized tissues, and sectioned to isolate the defect site.
The 3D reconstructed volumes were exported in Stere-
olithography (STL) file format and imported into reverse
engineering software (Geomagic Studio v12.0 software, 3D
SYSTEMS, Cary, NC, USA). Since file sizes were very large,
slowing down analysis, once volumes were reconstructed,
images were then trimmed in order to facilitate manipula-
tions. Landmarks to define the boundaries of surgical defects
were selected as 15mm, based on titanium plates used as
reference. The volumes present within confines of defects at
6 and 12 week postsurgical time points were quantified and
expressed in mm3.
2.6. Histology and Histomorphometry. Twelve weeks after
surgical procedure, the animals were euthanized. The speci-
menswere fixedwith 4% (v/v) paraformaldehyde for 24 hours
at room temperature. Samples were then decalcified in ethy-
lene diamine tetraacetic acid (EDTA) for 60 days. The sam-
ples were dehydrated in a graded ethanol series (70%, 95%,
and 100%) and embedded in paraffin. The specimens were
then serially sectioned (10𝜇m), deparaffinized, hydrated, and
stained with Hematoxylin and Eosin (H&E). The stained
sections were viewed under microscope (Olympus, Tokyo,
Japan) at various magnifications and digital images were
acquired. Quantitative histomorphometry was performed,
using NIH Image J software (U.S. National Institutes of
Health, Bethesda, Maryland, USA). Images taken at 40x were
used for histomorphometry. Standardized nomenclature was
used for defining various components of tissues within
each viewed field [23]. Newly formed bone volume (BV) is
defined as regions containing osteocytes within lacunae, the
proportion of which was calculated relative to that of total
tissue volume (TV).
2.7. Statistical Analysis of Data. Quantitative data were
presented as mean ± standard deviation (SD). Compar-
isons between two groups were performed using two-tailed
unpaired Student’s t-tests. Differences were considered statis-
tically significant at a 𝑃 value < 0.05.
3. Results
3.1. Clinical Outcomes. All animals healed uneventfully with-
out any adverse biologic complications. All surgical sites
showed minimal inflammation and no signs of infection.
Animals were euthanized at 12 weeks postsurgically.
3.2. Analysis of Mineralized Tissue Formation by CBCT. To
investigate the ability of the mAb to repair large critical-size
craniofacial defects, 15mm continuity defects were surgically
created in the posterior mandible and the two segments
were rigidly fixated with titanium reconstruction plates (Fig-
ure 1). The 15mm defect was filled with collagen scaffold
functionalized with chimeric anti-BMP-2 mAb or isotype-
matched control mAb. The areas were allowed to heal for
12 weeks. To investigate the kinetics of bone healing, serial
CBCT imaging was conducted preoperatively as well as 6
and 12 weeks postoperatively. The CBCT images (Figure 2)
were subjected to 2D and 3D quantitative analysis to deter-
mine the degree of bone healing within experimental and
control defects at the two postoperative time points. The
2D CBCT images were examined in three discrete planes,
that is, coronal, axial, and sagittal. Moreover, three different
zones within each of the axial planes (superior, middle,
and inferior) (Figure 2) were analyzed. Regions of interest
were defined within coronal (anterior, middle, and posterior)
and sagittal (anterior, middle, and posterior) planes (Supple-
mental Figure 1 in Supplementary Material available online
at https://doi.org/10.1155/2017/8094152). The bone density
within those defined regions is reported in Supplemental
Table 1.
Results demonstrated that mandibular defects implanted
with isotype-matched control mAb immobilized on collagen
scaffold exhibited very low density with negative HU at 6 and
12 weeks postoperatively (Figure 3). In contrast, mandibular
defects implanted with chimeric anti-BMP-2 mAb immo-
bilized on collagen scaffold exhibited significantly higher
density consistent with formation of mineralized tissue after
6 weeks, which increased by 12 weeks (Figure 3). Qualitative
examination of 2D and 3D reconstructed images illustrated
that new bone formation was observed at the margins of the
defect adjacent to resected parent bone.
Next, 3D volumetric measurement was performed for
tissues formed within surgical defects at 6 and 12 weeks post-
operatively (Figure 4(a)). Results revealed increasing bone
volume from 6 to 12 weeks in both experimentally treated
or control-treated defects. At both 6 and 12 weeks, there was
significantly more mineralized tissue volume, within defects
treated with chimeric anti-BMP-2 mAb (Figure 4(b)).
3.3. Histologic and Histomorphometric Analysis. To examine
the nature of biologic healing at the cellular level, qualita-
tive histological examination was performed on the treated
mandibles at 12 weeks postoperatively (Figure 5). Histological
evaluation revealed the presence of mature lamellar bone
containing osteocytes within lacunae within newly ossified
tissues in defects implanted with ACS functionalized with
anti-BMP-2 mAb (Figures 5(a)–5(e)). On the other hand,
defects implanted with ACS and isotype-matched control
mAb were occupied primarily by connective tissue (Figures
5(f)–5(j)). Similar to imaging data, histomicrographs illus-
trated that new bone formation was observed in direct appo-
sition to the margins of old bone. There was no evidence of
local inflammatory infiltration in either group. Quantitative
histomorphometric analysis revealed greater percentage of
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Figure 2: Representative 2D and 3D reconstructed CBCT images of mandibular continuity defects of experimental and control groups at 6
and 12 weeks postsurgically. 3D reconstructed CBCT images illustrate the landmarks used for axial plane sections for 2D image analysis.
Accordingly, axial sections were obtained at equal distances from the superior region of the mandibular defects, above titanium plates
(superior plane), as well as at middle (middle plane) and inferior regions (inferior plane) of the mandible. Representative 2D and 3D
reconstructed images of defects treated with isotype-matched control mAb (a, b) or chimeric anti-BMP-2 mAb (c, d) at 6 (a, c) and 12 (b, d)
time points are illustrated.
BV/TV within defects implanted with ACS functionalized
with anti-BMP-2 mAb compared with isotype-matched con-
trol mAb (Figure 5(k)).
4. Discussion
Autogenous bone grafting has long been regarded as the gold
standard for bone augmentation. However, there are many
disadvantages associated with this treatment modality such
as infection, hematoma, morbidity, and increased surgical
expense. The use of allografts, xenografts, and synthetic
biomaterials has enabled clinicians to avoid some of the
disadvantages of autografts; however, application of these
types of materials is still limited. As an alternative treat-
ment option, involving application of rhBMP-2 has been
widely used for bone regenerative procedures, providing a
promising alternative therapeutic option to autologous bone
grafting. However, there are several disadvantages associated
with the application of rhBMP-2. Recent studies from our
research group have demonstrated a tissue engineering strat-
egy involving immobilization of anti-BMP-2mAb on various
scaffolds implanted into surgical defect sites [14, 15, 17–20].
AMOR has been validated in calvarial defects of rats and
rabbits [14, 15, 17–20]. In order to advance this translational
project toward our ultimate goal of clinical trial, the present
investigation sought to utilize a clinically relevant defect in
an animal model that is phylogenetically closer to human. In
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Figure 3: Quantitative analysis of bone density within axial images of CBCTs taken presurgically and at 6 (a) and 12 (b) weeks postsurgically.
Bone density was measured within axial sections of CBCT images obtained from superior, middle, and inferior regions, according to the
landmarks illustrated in Figure 2.Themean density of experimental mandibular area at preoperative time point is presented for comparison.
Significantly higher bone density was observed within defects treated with chimeric anti-BMP-2 mAb compared to isotype-matched control
mAb (∗𝑃 < 0.05, ∗∗𝑃 < 0.01).
the present study, critical-size continuity mandibular defects
were generated in a nonhuman primate model. This is a
clinically relevant animalmodel,mimickingmany conditions
where craniofacial bones are resected due to neoplastic,
traumatic, or inflammatory lesions. Using this animal model,
which is closely associated with human, we demonstrated the
capacity of collagen scaffold functionalized with anti-BMP-2
mAb to mediate de novo bone formation within mandibular
continuity defects. These data confirmed and extended our
previous studies, demonstrating the efficacy of AMOR in
rodents and rabbits [17–20].
Before a tissue engineering approach can be critically
examined in a clinical trial, confirming the findings in a
large animal model that closely mimics the clinical condition
being studied is required [24, 25]. Our results provide further
evidence in support of AMOR as a translational approach.
Its efficacy and reproducibility have been demonstrated in a
number of animals with different defect models [14–20].
The present experimental model is the largest defect
which we have utilized to investigate the mechanism of
AMOR. The present model has provided significant insights
into the mechanism of osteogenesis within these defect sites.
Firstly, the fact that application of anti-BMP-2 mAbs that
were generated in a murine host against human BMP-2
antigen led to repair of large critical-size defects in mon-
keys suggests that this antibody is capable of capturing
endogenous monkey BMP ligands. This may be attributed to
the high degree of homology between human and monkey
BMP molecules [26]. Secondly, two possible mechanisms
may be suggested for osteogenesis through AMOR: (1)
osteoconduction, that is, bone formation by direct opposition
on parent bone, and (2) de novo bone formation, which
is bone repair without existing bone template. The present
experiment showed bone repair was initiated and propagated
at themargins of surgical defects. It may be hypothesized that
the concentrations of endogenous BMPs are greatest at host
bone that is responsible for this pattern of bone formation.
Over the past three decades, monoclonal antibody ther-
apy has become one of the fastest growing areas of bio-
pharmaceutical applications. The reason for the increasing
popularity of therapeutic mAbs is their safety profile, high
degree of specificity, diversity, and relatively low cost. The
majority of current therapeuticmAbs are utilized for targeted
therapy in three main areas, namely, cancer, immunity, and
inflammation [27]. To date, the primary route of antibody
administration is systemic administration, which may cause
“infusion reaction” [27]. In the present study, anti-BMP-2
mAb was delivered using a collagen scaffold and implanted
locally into the defect sites to mediate de novo bone for-
mation. We have previously demonstrated that the locally
implanted anti-BMP-2 mAb is slowly released, though it
persists for at least 8 weeks [15, 19]. There were no side
effects or adverse events detected in the current study. This
is consistent with previous studies conducted in other animal
models [17–20], suggesting the safety of local administration
of anti-BMP-2 mAbs.
It has been demonstrated that BMPs in solution are
quickly cleared from the body, which may explain why high
doses of exogenous rhBMPs are needed for tissue regen-
eration [16]. The high dose of rhBMP currently approved
by the FDA (1.5mg/mL) is several orders of magnitude
above physiological levels. Significant complications have
BioMed Research International 7
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Figure 4: 3D analysis of bone volume within surgical defect. Mandibular continuity defects were treated with chimeric anti-BMP-2 mAb
compared to isotype-matched control mAb. CBCT images taken at 6 and 12 weeks postsurgically and the volume of bone within the defect
sites at two time points was quantified (a). Quantitative analysis of bone volume (mm3) within defects treated with chimeric anti-BMP-2mAb
or isotype-matched control mAb (b). Significantly higher bone volume was detected within defects treated with chimeric anti-BMP-2 mAb
compared to isotype-matched control mAb at both time points (∗∗𝑃 < 0.01).
been reported following rhBMP-2 administration, perhaps
due to the superphysiologic concentration [28]. In the present
study, we used ACS as the scaffold for immobilizing anti-
BMP-2 mAb and observed significant de novo bone for-
mation in large critical-size mandibular continuity defects.
The contrasts between the application of exogenous growth
factors and in situ trapping of endogenous growth factors by
specific monoclonal antibodies are multifold:
(1) Spatial and temporal availability of growth factors is
linked to the biological process of wound healing.
In normal biological wound healing, growth factors
need to be present at the appropriate concentration in
the local microenvironment at the appropriate time.
In some circumstances, the availability of growth
factors at an inappropriate time can have the opposite
of the intended effect.
(2) Endogenous growth factors have higher biological
activity than their recombinant counterparts, pre-
sumably due to differences in posttranslational mod-
ification of endogenous growth factors.
(3) Antibodies have excellent safety profiles, particularly
when delivered locally as in AMOR.
In AMOR, the availability of growth factors is orchestrated by
endogenous expression of those growth factors, expressed at
the appropriate stage in the cascade of events during wound
healing. AMOR merely amplifies the effects of the growth
factors by facilitating their local accumulation via specific
mAbs.
Since antibody therapy has been associated with some
potential adverse reactions [29], it was important to address
this issue. We carefully examined our histologic sections of
mandible for presence of any signs of adverse reaction such
8 BioMed Research International
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Figure 5: Histologic and histomorphometric analysis of treated mandibular defects. Histomicrographs of H&E stained sections obtained
from axial planes taken at the midpoint between superior and inferior boundaries of mandibular defects (a–j). Mandibular segmental
osteotomy defects were treated with chimeric anti-BMP-2 mAb (a–e) or isotype-matched control mAb (f–j) immobilized on absorbable
collagen sponge scaffold. Histological evaluation 12 weeks after surgery revealed the presence of mature lamellar bone in the newly ossified
tissue of experimental defect treated with chimeric anti-BMP-2 mAb (a–e), whereas isotype-matched control mAb (f–j) was primarily filled
with connective tissue.Therewas no evidence of inflammatory infiltration in either group. Black and green arrowheads represent osteoid bone
or all other tissues (referred to as void), respectively. Quantitative histomorphometric analysis of new bone formation (k) confirmed higher
degree of bone formation within defects treated with chimeric anti-BMP-2 mAb compared with isotype-matched control mAb (∗∗𝑃 < 0.01).
as exuberant inflammatory infiltrate and we did not observe
significant inflammatory infiltrate in experimental or control
sites. This is most likely due to the fact that the volume
of diluted mAb solution (150 𝜇L) at 25 𝜇g/mL concentration
used for incubation with the scaffolds entails maximum of
3.75 𝜇g of mAb administered. This dose is far lower than
those used for typical therapeutic mAbs that are clinically
administered.Moreover, sinceAMORentails applyingmAbs,
which are immobilized on solid scaffold, the potential for
adverse reaction is likely lower than most therapeutic mAbs
which are systemically administered.
In view of the many complications and limitations
reported for the current gold standard of bone repair (e.g.,
autogenous grafting) and the newer technology of recom-
binant growth factor therapy, there is currently a need for
safe and effective alternatives for the treatment of significant
skeletal defects. AMOR presents a viable alternative strategy
and merits further investigation. Although chimeric anti-
bodies are currently approved by the US FDA for clinical
use, most of the therapeutic antibodies currently in use are
humanized or fully human. Humanized antibodies are gener-
ated by transfer of the complementarity determining region
(CDR) of the antibody from another species onto a human
Ab. Therefore, before clinical studies can be conducted on
AMOR, humanized antibodies have to be generated. Cur-
rently, generation of humanized anti-BMP-2mAbs which are
suitable for clinical testing is in the planning stages.
5. Conclusion
In the present study, chimeric anti-BMP-2 mAb immobilized
onACS scaffold promoted de novo bone formation efficiently,
as confirmed by a novel clinically relevant mandibular conti-
nuity defect in a nonhuman primate model. Altogether, our
data demonstrate the efficacy of chimeric anti-BMP-2 mAb
for bone tissue engineering applications. The strategy pro-
posed herein has amultitude of potential clinical applications
in the repair of skeletal defects due to congenital, traumatic,
neoplastic, or inflammatory processes.
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